V8 Peptides — Engineered Performance
Research Library
TB-500: Angiogenesis and Cell Migration Assay Guide
TB-500Preclinical

TB-500: Angiogenesis and Cell Migration Assay Guide

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How is TB-500 studied in angiogenesis and cell-migration models? Through classic in vitro assays: endothelial scratch (wound-closure) assays, transwell or Boyden-chamber migration, tube formation on basement-membrane matrix, and aortic-ring or chorioallantoic membrane preparations. The published work comes mostly from thymosin β4 (Tβ4), the parent protein, which binds G-actin and was reported to promote endothelial migration and tube formation. A 2003 study located activity in the actin-binding region, LKKTETQ, which is the sequence the TB-500 research vial corresponds to. This article is an assay-design guide for laboratory use only; results from Tβ4 should not be assumed to apply to the fragment.

Cell migration and angiogenesis are readouts, not mechanisms. Calling a peptide "pro-migratory" is meaningful only when the assay, the cell type, the matrix, the concentration range and the timing are all stated. This page walks through the standard assay formats used with thymosin β4 and its actin-binding fragment, the controls each needs, and the points where results are most often over-read. It sits beside the TB-500 research overview and the companion history of TB-500 and thymosin β4 research, and focuses on the experimental side.

The biology that makes these assays relevant

Cells move by assembling actin filaments at the leading edge and disassembling them behind it. Pollard and Borisy (2003) describe this cycle in detail: new filaments grow from a pool of monomeric actin, and the rate of growth depends on how much unpolymerized actin is available. Thymosin β4 is the major G-actin-sequestering protein in many cells. It holds actin monomers in a reserve that can be released to filament ends (Safer and colleagues, 1991; Huff and colleagues, 2001). That is the mechanistic link between a small acidic peptide and a behavior as large as migration, and it explains why endothelial cells, which must migrate to form vessels, became the first test system.

What the key papers reported

Malinda and colleagues (1997) reported that Tβ4 stimulated directional migration of human umbilical vein endothelial cells (HUVEC) in a chamber assay. Grant and colleagues (1999) reported that it enhanced endothelial differentiation into tube-like structures on Matrigel and angiogenic responses in a further assay. Philp and colleagues (2003) examined which part of the protein carried the activity and reported that the actin-binding site, the region around LKKTETQ, promoted angiogenesis. Later authors added work on integrin-linked kinase signaling (Bock-Marquette and colleagues, 2004) and on tissue models, including the cornea (Sosne and colleagues, 2002). Each paper used its own concentration, matrix and readout, and the papers are best read as a set of system-specific observations rather than one generalizable effect.

Assay formats at a glance

AssayWhat is measuredStrengthsCommon pitfalls
Scratch (wound-closure) assayGap closure over hoursCheap; simple imagingProliferation can masquerade as migration; scratch width varies
Transwell or Boyden chamberCells crossing a porous membrane toward a gradientDirectional, quantifiablePore size, coating and incubation time shift the window
Tube formation on basement-membrane matrixNodes, loops and tube lengthFast readout of differentiationLot-to-lot matrix variation; sensitive to cell passage
Aortic ring or similar explantSprouting from tissuePreserves multiple cell typesVariability between animals and rings
Chorioallantoic membrane preparationVessel branching in an embryo membraneWhole-tissue contextRegulatory and ethical review; vehicle effects

Controls that make a migration result credible

  • Vehicle control with the same diluent, including any preservative, in every arm.
  • Positive control, such as VEGF or serum gradient, so the assay is shown to respond.
  • Proliferation control. Run a viability or proliferation assay in parallel, or add a proliferation inhibitor in a scratch assay, to separate movement from division.
  • Sequence-scrambled or inactive peptide of similar length and charge to control for nonspecific peptide effects.
  • Full-length versus fragment comparison when the question is whether the actin-binding region is sufficient.
  • Cell-type and passage control. Use low-passage endothelial cells and record the passage number.

Designing the concentration range

Peptide effects in migration assays are often non-monotonic, and a bell-shaped curve is common in chemotaxis. A single concentration can therefore miss the response or land on the declining arm. A range spanning several logarithmic steps, with replicates, is a more reliable design. Concentration arithmetic is formula-based: stock concentration in mg/mL equals vial mass divided by diluent volume, molar concentration equals mass concentration divided by molecular weight (about 889 Da for the 17–23 fragment, as stated on the product page), and each serial dilution step multiplies by its dilution factor. The reconstitution calculator performs the first two conversions. For short acetylated heptapeptides, correcting for net peptide content matters because counter-ions and water make up a large share of the powder (Sikora and colleagues, 2020).

Material and handling considerations

The product page describes TB-500 as the synthetic 17–23 fragment of Thymosin β4, Ac-LKKTETQ, molecular formula C38H68N10O14, supplied as a lyophilized powder in a 10 mg size with purity specified at ≥98% by HPLC. Storage is refrigerated at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light. A COA is shown where published, and the COA library is the place to check. Short hydrophilic peptides tend to dissolve readily, but they are also small enough to be lost on surfaces at low concentration, so low-binding labware and late dilution still apply (Goebel-Stengel and colleagues, 2011). General technique is covered in how to reconstitute a lyophilized peptide, and identity checks are explained in TB-500 purity testing.

Common ways angiogenesis data are over-read

ObservationOver-readingMore careful reading
More tube nodes on matrix"Promotes angiogenesis"Increased endothelial network formation in one in vitro assay
Faster scratch closure"Promotes migration"Faster closure, possibly with a proliferation contribution
Effect with full-length Tβ4"Applies to the fragment"Needs the fragment tested directly
Effect in HUVEC"Applies to all vessels"Endothelial source (macro- versus microvascular) may matter
Effect in a short assay"Lasting response"Time course needed

Practical notes on running the assays

Endothelial cells are demanding. Primary HUVEC lose their phenotype with passage, so experiments should use early passages and record them. Serum content changes baseline migration, so many laboratories lower serum or use a defined low-serum medium during the assay to reduce background movement; the same medium must be used in every arm. For scratch assays, make the gap with a consistent tool, wash away debris, and image the same fields at each time point, because comparing different fields adds variance larger than most treatment effects. For transwell assays, coat membranes uniformly, count cells in several random fields per insert, and keep the incubation time inside the linear range of the assay. For tube formation, seed a fixed number of cells onto matrix of the same lot and thickness, and quantify at a fixed time, since networks form and then regress.

Finally, pre-register the analysis in the notebook: which metric, which fields, which exclusions. Deciding after seeing the images invites unconscious selection, and that is the most common reason a migration result fails to replicate.

A last point on statistics: migration assays produce count or area data with technical replicates nested inside biological replicates. Take the independent experiment, not the individual field or well, as the unit of analysis, and report how many independent experiments were run. Pooling fields as if they were independent inflates apparent significance and is a frequent reason a published effect shrinks on repetition.

Reporting checklist

A reproducible report names the cell line or primary source, passage, medium and serum content, matrix and lot, peptide identity and lot, concentration series, assay duration, imaging method, number of biological and technical replicates, and the statistical test used. Quantify images with predefined, blinded criteria where possible. Where a laboratory also works with related materials, BPC-157 vs TB-500 explains how the literatures differ, so assays are not cross-attributed.

Limits of the literature

Most evidence for Tβ4 comes from full-length protein, and the fragment has a much smaller direct literature. Reviews such as Goldstein and colleagues (2005) are useful for orientation, but they summarize observations from multiple systems and do not establish a single mechanism. Nothing here describes use outside the laboratory, and no amount or schedule for animals is suggested. If a project needs in vivo data, the responsible path is a published protocol approved by an institutional committee, not an extrapolation from a cell assay.

All material discussed here is supplied for laboratory research use only; not for human consumption, not a drug, food or cosmetic.

Related reading

Frequently asked questions

Which assays are used to study TB-500 and cell migration?

Scratch assays, transwell or Boyden chamber assays, tube formation on basement-membrane matrix, and explant or membrane preparations. Each reports a different aspect of migration or differentiation.

Is TB-500 the same as thymosin β4?

On the V8 product page TB-500 is the 17–23 fragment, Ac-LKKTETQ. Thymosin β4 is the full 43-residue protein, and most published migration data come from the full-length protein.

Why is actin relevant to migration?

Cells advance by assembling actin filaments at the leading edge, and thymosin β4 holds monomeric actin in reserve, which links it to the speed of that assembly.

What did Philp and colleagues report in 2003?

That the actin-binding site of thymosin β4, centered on LKKTETQ, promoted angiogenesis in assays, supporting research on short fragments.

How can proliferation be separated from migration?

Run a viability assay in parallel, use a proliferation inhibitor in scratch assays, or choose a transwell format with a short incubation time.

What controls should a TB-500 assay include?

Vehicle, a positive control such as VEGF, a scrambled or inactive peptide, a full-length comparison, and matched cell passage.

Why test several concentrations?

Chemotactic responses are often bell-shaped, so a single concentration can fall outside the response range.

How do I calculate the stock concentration?

Divide vial mass by diluent volume, then divide by molecular weight for molarity, correcting for net peptide content. The calculator performs the conversion.

What does the product page list for TB-500?

The 17–23 fragment Ac-LKKTETQ, formula C38H68N10O14, 10 mg lyophilized vial, ≥98% HPLC purity specification, for laboratory research use only.

How should the powder be stored?

The product page states refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Related reading: TB-500 Laboratory Safety and Handling Guide, TB-500: Actin-Binding Motif and Cell Migration Assays.

Related reading: Wolverine Stack Research Design: BPC-157 + TB-500 Ratios.

References

  1. Malinda KM, Goldstein AL, Kleinman HK. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. doi:10.1096/fasebj.11.6.9194528
  2. Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. Thymosin β4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-135. doi:10.1023/A:1009041911493
  3. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje
  4. Huff T, Müller CSG, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. doi:10.1016/S1357-2725(00)00087-X
  5. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112(4):453-465. doi:10.1016/S0092-8674(03)00120-X
  6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004
  7. Sosne G, Chan CC, Thai K, et al. Thymosin β4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72(5):605-608. doi:10.1006/exer.2000.0985
  8. Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides: an overview. Pharmaceuticals (Basel). 2020;13(12):442. doi:10.3390/ph13120442

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.